Infection in pregnancy and cerebral palsy

Developmental Medicine and Child Neurology

Volumn 51, Issue 4, 2009, Pages 253-

  Nelson, Karin B ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYTOKINE;

ATTRIBUTABLE RISK; CEREBRAL PALSY; CHORIOAMNIONITIS; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE ASSOCIATION; FETUS; FETUS RISK; HUMAN; NEUROPATHOLOGY; NOTE; PLACENTAL TRANSFER; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PUERPERAL INFECTION; RISK FACTOR; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; CEREBRAL PALSY; FEMALE; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; URINARY TRACT INFECTIONS;

EID: 63049105664     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2008.03256.x     Document Type: Note

References (7)

1. Spinillo A, Capuzzo E, Stronati M, Ometto A, De Santolo, Acciano S. Obstetric risk factors for periventricular leukomalacia among preterm infants. Br J Obstet Gynaecol 1998; 105:865-71.
2. Neufeld MD, Frigon C, Graham AS, Mueller BA. Maternal infection and risk of cerebral palsy in term and preterm infants. J Perinatol 2005; 25:108-13.
3. Nelson KB, Ellenberg JH. Antecedents of cerebral palsy. I. Univariate analysis of risks. Am J Dis Child 1985; 139:1031-38.
4. Palmer L, Blair E, Petterson B, Burton P. Antenatal antecedents of moderate and severe cerebral palsy. Paediatr Perinat Epidemiol 1995; 9:171-84.
5. Camp BW, Broman SW, Nichols PL, Leff M. Maternal and neonatal risk factors for mental retardation: Defining the 'at-risk'child. Early Hum Dev 1998; 50:159-73.
6. Berger A, Witt A, Haiden N, et al. Intrauterine infection with Ureaplasma species is associated with adverse neuromotor outcome at 1 and 2 years adjusted age in preterm infants. J Perinat Med 2009; 37:72-78.
7. Kenyon S, Pike K, Jones DR, et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet 2008; 372:1319-27.